<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04600180</url>
  </required_header>
  <id_info>
    <org_study_id>202000666</org_study_id>
    <nct_id>NCT04600180</nct_id>
  </id_info>
  <brief_title>The Gut Immune System During Immune Checkpoint Inhibitor Therapy</brief_title>
  <acronym>DEFENCE</acronym>
  <official_title>Deep Phenotyping of the Gut Immune System During Immune Checkpoint Inhibitor Therapy - DEFENCE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This exploratory study aims to gain insight in gut immune system phenotypes before and after&#xD;
      immunotherapy. After informed consent is obtained, sigmoidoscopies at baseline and during&#xD;
      treatment with immunotherapy will be performed, During the endoscopies, biopsies from the&#xD;
      sigmoid and rectum will be obtained. Subsequent immune cell analyses in these biopsies will&#xD;
      be performed. Parallel to the sigmoidoscopies, venous blood samples will be obtained to&#xD;
      monitor inflammatory markers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CD8+ T cell count in the gut mucosa</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Palliative treatment with immunotherapy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sigmoidoscopies and and venous blood sampling</intervention_name>
    <description>Sigmoidoscopies will be performed at baseline and during immunotherapy. During these procedures biopsies will be taken from the sigmoid and rectum. At the same timepoints, venous blood samples will be taken.</description>
    <arm_group_label>Palliative treatment with immunotherapy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Gut wall biopsies and venous blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with cancer and an indication for palliative treatment with immune&#xD;
        checkpoint inhibitors.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Indication for treatment with anti PD1/PDL1 based immunotherapy&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Evaluable according to iRECIST v1.1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant, chronic or infectious illness in the past 6 months causing moderate to&#xD;
             severe colitis&#xD;
&#xD;
          -  Use of a medication in the past 6 months with an elevated risk of moderate to severe&#xD;
             colitis&#xD;
&#xD;
          -  Gastrointestinal resection or enterostomy&#xD;
&#xD;
          -  Abdominal radiotherapy in the past 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacco J. de Haan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacco J. de Haan, MD, PhD</last_name>
    <phone>+31 50 361 61 61</phone>
    <email>j.j.de.haan@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wouter B. Nagengast, Prof.</last_name>
    <phone>+31 50 361 61 61</phone>
    <email>w.b.nagengast@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacco J. de Haan, MD, PhD</last_name>
      <phone>+31 50 361 61 61</phone>
      <email>j.j.de.haan@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Wouter B. Nagengast, Prof.</last_name>
      <phone>+31 50 361 61 61</phone>
      <email>w.b.nagengast@umcg.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Jacco J. de Haan, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Dr. J.J. de Haan</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Immune Checkpoint Inhibitor</keyword>
  <keyword>Cancer</keyword>
  <keyword>Gut Wall</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

